A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2019
At a glance
- Drugs BT-11 (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Landos Biopharma
- 07 Jan 2019 Results presented in the Landos Biopharma media release.
- 12 Jul 2018 According to a Landos Biopharma media release,,Status changed from planning to recruiting.
- 12 Jul 2018 According to a Landos Biopharma media release, first healthy subjects have been dosed in this study.